Metabolic traits of cancer stem cells
Joana Peixoto¹,²,³,⁴ and Jorge Lima¹,²,³,*

ABSTRACT
Cancer stem cells are a subpopulation of cells within a tumour believed to confer resistance to standard cancer therapies. Although many studies have addressed the specific mechanisms of tumour recurrence driven by cancer stem cells, cellular metabolism is an often-neglected attribute. The metabolic features of cancer stem cells are still poorly understood, and they thus constitute a promising field in cancer research. The findings published so far point to a distinct metabolic phenotype in cancer stem cells, which might depend on the cancer type, the model system used or even the experimental design, and several controversies still need to be tackled. This Review describes the metabolic phenotype of cancer stem cells by addressing the main metabolic traits in different tumours, including glycolysis and oxidative, glutamine, fatty acid and amino acid metabolism. In the context of these pathways, we also mention the specific alterations in metabolic enzymes and metabolite levels that have a role in the regulation of cancer stemness. Determining the role of metabolism in supporting resistance to therapy driven by cancer stem cells can raise the opportunity for novel therapeutic targets, which might not only eliminate this resistant population, but, more importantly, eradicate the whole tumour in a relapse-free scenario.

KEY WORDS: Cancer metabolism, Cancer stem cells, Therapy resistance, Tumour heterogeneity

Introduction
Cancer is widely known to be a heterogeneous disease, in which malignant cells communicate with various other cell types, such as endothelial, haematopoietic and stromal cells (see Glossary, Box 1). This complex system within a tumour can influence its own behaviour. Although it is clear that tumour heterogeneity is related to progression, therapy resistance and recurrence, the mechanisms behind these links are still to be uncovered. In this context, a subpopulation of cells within the tumour with the potential for long-term clonal growth and self-renewal capacities – the so-called cancer stem-like cells (CSCs) – has been described as a driver of tumour survival and resistance against commonly used cancer therapies.

The role of these cells in several cancers has been studied frequently, aiming at disclosing the molecular programs that govern and maintain the stemness (Box 1) of this population. One of these molecular programs encompasses metabolic alterations, which could potentially become important targets for therapies aimed at eliminating this resistant cell population. This Review focuses on the metabolism of cancer stem cells, which is currently an emerging hot topic that researchers need to address further and in a systematic way.

Stem cells and cancer stem cells
In the late 19th century, Ernst Haeckel used the term stem cell (SC) for the first time to designate the committed cell that gives rise to the germline of an organism. Later in that century, Theodor Boveri and Valentin Häcker pursued and ameliorated the concept of SCs in their embryological studies (Boveri, 1892; Häcker, 1892). In parallel, Artur Pappenheim used the same term to describe the cell that is at the basis of the evolving genealogy of haematopoiesis (Box 1). It was only in the 1960s that James Till, Ernest McCulloch and others provided clear evidence for the existence of a common haematopoietic SC (Till and McCulloch, 1961; Till et al., 1964). These discoveries allowed the establishment of the term SC, which is nowadays used to define a cell capable of proliferating indefinitely and give rise to specialized daughter cells. By raising many questions regarding embryonic development, cellular differentiation and organ maintenance, the role of SCs began to be exploited in disease settings, specifically in cancer (Ramalho-Santos and Willenbring, 2007).

Intratumour heterogeneity – the hierarchical and stochastic models
The concept of CSCs being identified by the expression of a combination of markers, and the fact that these distinct populations are able to develop a secondary tumour that recapitulates the properties of the primary tumour, was confirmed in several studies (Box 2). Therefore, the CSC model originally postulated a unidirectional hierarchy, where asymmetric and symmetric divisions of CSCs produce the bulk of the tumour to generate differentiated cancer cells and to self-renew the CSC pool, respectively. However, other studies questioned the universality of this hierarchical model, as they showed that cancer cell plasticity often occurs in tumours and that CSCs participate in this process (Nassar and Blanpain, 2016; Prasetyanti and Medema, 2017). For example, stem-like basal and luminal cell populations isolated from human breast cancer cell lines could reversibly convert into distinct cell states to produce the same three subpopulations in similar proportions to the original cell line they were isolated from. However, only the stem-like cells were able to generate tumours upon xenotransplantation, a typical feature of CSCs (Gupta et al., 2011). In a melanoma model, the CSCs expressing the surface marker CD127 were shown to be tumourigenic, but were also able to arise from CD127− progeny, again indicating the reversible phenotype of cancer cells (Quintana et al., 2010; Civenni et al., 2011). Also in melanoma, the expression of the histone demethylase (Box 1) JARID1B (also known as KDM5B) defines a population of slow-cycling cells with tumorigenic potential, i.e. CSCs. Interestingly, JARID1B− cells were shown to re-express the
Temozolomide: a platinum-based chemotherapeutic drug used to treat several cancers, including sarcomas, lung cancer, ovarian cancer, lymphomas and germ cell tumours.

Endothelial cells: a group of cells that form the surface of blood and lymphatic vessels and function as a barrier between the vessel lumen and the surrounding tissue, being involved in the formation of new blood vessels (angiogenesis).

Fluorodeoxyglucose-positron emission tomography (FDG-PET): an imaging technique that uses a glucose analog (FDG) for the visualization of solid cancers. This technique relies on the fact that cancer cells have increased glucose uptake, providing valuable information regarding the localization and size of the tumour for diagnosis, staging and monitoring purposes.

Haematopoietic stem cells: stem cells generally found in the bone marrow that produce all the different blood cell types, by progressing through committed progenitor stages until they fully differentiate into mature cells.

Haematopoietic cells: cells that form the surface of blood and lymphatic vessels and function as a barrier between the vessel lumen and the surrounding tissue, being involved in the formation of new blood vessels (angiogenesis).

Haematopoietic stem cells: stem cells generally found in the bone marrow that produce all the different blood cell types, by progressing through committed progenitor stages until they fully differentiate into mature cells.

Hemodialysis: the process that yields the formation of blood cells, from a stem cell into a fully differentiated blood cell.

Haematopoietic: cells: stem cells generally found in the bone marrow that produce all the different blood cell types, by progressing through committed progenitor stages until they fully differentiate into mature cells.

Hexosamine pathway: a branch of the glycolysis pathway in which the building blocks for glycosyl side chains of proteins and lipids are produced. It is associated with post-translational modifications, specifically glycosylation.

Histone demethylase: an enzyme responsible for removing methyl groups from histones that regulate chromatin architecture.

Induced pluripotent stem cells: a type of pluripotent stem cell derived from adult cells by introducing a specific set of reprogramming factors, which induce pluripotency-associated genes.

Intestinal crypts: anatomical units where intestinal stem cells are located for the active self-renewal of the intestinal epithelium.

Leukotrienes: a family of eicosanoid inflammatory mediators produced by leukocytes, mast cells, macrophages and other cells, in response to immunological stimuli.

Mammospheres: round-shaped structures of mammary cells, formed in vitro under certain culture conditions to enrich for stem cells.

Mefin: a benzamide drug used as a first-line therapy for type 2 diabetes. It is also used as an antitumour agent that affects metabolism by directly inhibiting respiratory chain complex I in the mitochondria.

Nanog: a DNA-binding homeobox transcription factor involved in self-renewal and undifferentiation of embryonic stem cells. It is also broadly expressed in human cancers, thus used as a cancer stem cell marker.

Paclitaxel: a chemotherapeutic drug that binds to tubulin and inhibits the disassembly of microtubules, ultimately inhibiting cell division.

Paneth cells: a group of connective tissue cells (such as fibroblasts) that support the function of other cells within an organ.

Paneth cells: a group of connective tissue cells (such as fibroblasts) that support the function of other cells within an organ.

Pentose phosphate pathway (PPP): a multi-step metabolic pathway parallel to glycolysis for the oxidation of glucose, which produces NADPH and ribose 5-phosphate that can be used for nucleotide synthesis.

Satellite muscle cells: quiescent stem cells of the skeletal muscle that function as a reserve population of cells and proliferate in response to injury.

Secretome: the collection of factors released by a cell, including extracellular matrix proteins, transmembrane proteins and vesicle proteins.

Stemness: the essential trait of stem cells: their ability to self-renew and differentiate into various committed cells.

Stromal cells: a group of connective tissue cells (such as fibroblasts) that support the function of other cells within an organ.

Temozolomide: an alkylating chemotherapeutic drug used as treatment for brain tumours.

13C-glucose: a nonradioactive naturally occurring glucose isotopomer in which all six carbons are 13C labelled.

Altered metabolism as a hallmark of cancer

The reprogramming of cellular energy metabolism is a classical feature of cancer, mainly used by cancer cells to sustain their highly proliferative status (Hanahan and Weinberg, 2011). Under aerobic conditions, normal nonproliferating cells use glycolysis in the cytoplasm to form pyruvate, which is then oxidized in mitochondrial oxidative phosphorylation (OXPHOS) to generate energy in the form of adenosine triphosphate (ATP). Under anoxic conditions, glycolysis-derived pyruvate is mainly directed to lactate production. In contrast, cancer cells rely more on glycolysis for energy production even in the presence of oxygen, a phenomenon first observed by Otto Warburg and termed ‘aerobic glycolysis’ or the ‘Warburg effect’ (Warburg, 1956a,b).

This metabolic adaptation, although generating ATP more rapidly, is far less efficient than OXPHOS, resulting in abnormally high glucose uptake to sustain ATP production. The avidity of cancer cells for glucose, mainly mediated by the upregulation of glucose transporter 1 (GLUT1; also known as SLC2A1), contributed to the development of fluorodeoxyglucose-positron emission tomography (FDG-PET, Box 1) techniques for cancer detection and monitoring (Vander Heiden et al., 2009).

As demonstrated in several studies discussed below, increased glycolysis allows the production of several metabolic intermediates that can feed alternative biosynthetic pathways to generate macromolecules, such as nucleosides, amino acids and lipids, which can then be used as building blocks to support the high proliferation and division rates of cancer cells, conferring a selective advantage.

The factors underlying the metabolic alterations of cancer cells are the subject of intense study. Oncogenes or tumour suppressors, but also the tumour microenvironment (TME), can reprogram
Box 2. Cancer stem cells

Tumour heterogeneity is often reflected in the expression of many different histological markers, despite the fact that tumours are believed to arise from a single mutated cell (Nassar and Blanpain, 2016). Advanced technologies, such as fluorescence-activated cell sorting and mouse xenografts assays, allowed studies in haematopoietic stem cells (SCs) that delivered sets of cell-surface markers, which were crucial for defining tumour heterogeneity in acute myeloid leukaemias. Lapidot and colleagues found that only the population of leukaemic cells that were positive for CD34 and negative for CD38 (CD34+CD38−) could initiate leukaemic engraftment in immune-deficient mice, and that the frequency of these tumour-initiating cells was about one per million cancer cells (Lapidot et al., 1994; Bonnet and Dick, 1997). The term cancer stem-like cells (CSCs) was then coined to define a small population of cells within the cancer that expresses specific markers, and that, when transplanted in immune-deficient mice, is able to recapitulate some of the heterogeneity of the original malignancy (Cleurs, 2011; Battle and Clevers, 2017).

These findings were subsequently recapitulated in studies of solid tumours. Breast cancer was the first human tumour demonstrated to consist of heterogeneous populations of cells, specifically a subpopulation capable of initiating tumour growth in immune-deficient mice. These cells were phenotypically CD44+CD24−low and as few as 100 cells were capable of forming tumours, in contrast to the tens of thousands of cells with other phenotypes that could not reform tumours in mice (Al-Hajj et al., 2003). Moreover, using the same experimental approaches, the specific markers that pinpointed those cells to initiate tumours in immune-deficient mice were identified in several other malignancies, such as pancreatic (Herrmann et al., 2007; Li et al., 2007) and colon cancer (O’Brien et al., 2007; Ricci-Vitiani et al., 2007), melanoma (Schlaten et al., 2008; Boiko et al., 2010), ovarian (Zhang et al., 2008) and lung cancer (Ermo et al., 2008), and brain tumours (Singh et al., 2004; Chen et al., 2010). However, it became clear that the cell transplantation assay was mainly appropriate for haematological malignancies, in which a defined stem-progenitor hierarchy, with specific markers, was validated in normal haematopoietic SCs and used for the definition of leukaemia SCs (Lapidot et al., 1994; Bonnet and Dick, 1997).

In most solid cancers, this cellular hierarchy and the specific markers for the tissue of origin are still unknown. Commonly used markers, such as CD133, have been extensively used in brain (Singh et al., 2004; Bao et al., 2006) and colon tumours (O’Brien et al., 2007; Ricci-Vitiani et al., 2007) for the characterization of CSCs, but the reproducibility of the findings using this marker has been questioned (Shmelkov et al., 2008; Wang et al., 2008; Chen et al., 2010). Moreover, when sorted for a specific marker, both marker-positive and -negative populations were capable of regenerating the original marker expression of the tumour (Shackleton et al., 2009; Quintana et al., 2010). The fact that intratumour heterogeneity is more pronounced in solid tumours than in leukaemias, together with the lack of specific marker CSCs, also limits the universality of this approach for the study of SCs (Battle and Clevers, 2017). It should also be noted that transplantation studies are limited to demonstrating that a specific cell population adapts to particular assay conditions, and thus cannot disclose the fate of these cells in their original microenvironment (Cleurs, 2011; Nassar and Blanpain, 2016).

In an attempt to overcome the aforementioned limitations, researchers developed genetic lineage-tracing approaches for stem cell studies. The advantage of lineage tracing, as opposed to isolation and transplantation studies, is that knowing which markers are expressed by the cell of interest is not required. When tracing a particular cell type by permanently labelling its progeny with a reporter gene, it is possible to identify cells with SC potential and provide insights into the dynamics of stem and progenitor cells during development, tissue maintenance and repair and, ultimately, their dysregulation in cancer (Kretzschmar and Watt, 2012; Blanpain and Simons, 2013).

Lineage tracing in tumours provided the evidence of a hierarchical organization in solid tumours and therefore consistently proved the existence of CSCs. Lineage tracing of the basal-cell-specific keratin 14 in papillomas demonstrated the long-term survival of a population of cells, which gave rise to large clonal populations within the tumour (Driessens et al., 2012). Another study in a breast cancer mouse model demonstrated that some clones rapidly grew, becoming dominant. CSCs were the origin of these dominant clones and were able to divide into differentiated tumour cells and into new SCs to sustain tumour growth (Zomer et al., 2013). In colorectal cancer patient-derived organoids, the use of CRISPR-Cas9 gene editing to insert cassettes into the LGR5 locus – a biomarker of adult stem cells in certain tissues – enabled lineage tracing and revealed that LGR5+ cells survive for long time periods, producing progenies that are capable of forming tumours (Cortina et al., 2017; Shimokawa et al., 2017). The formation of large clonal populations from APC-deleted Lgr5+ cells was observed by lineage tracing, enabling the identification of SCs in a mouse model of intestinal adenoma (Schepers et al., 2012; Kozar et al., 2013). Furthermore, Chen et al. used a genetically engineered mouse glioma model with a Nes-iTK-ires-GFP transgene and identified a population of endogenous cells that were responsible for tumour recurrence. This transgene labelled normal brain SCs in the subventricular zone and also a restricted population of slow-cycling endogenous glioma cells. After tumour proliferation arrest, the nestin+ cells re-entered the cell cycle and produced highly proliferative cells that contributed to tumour relapse. Targeted ablation of these cells inhibited tumour progression and recurrence. This study showed that nestin+ cells had CSC-like properties, because they demonstrated the capacity of long-term tumour growth and mediated tumour relapse following therapy (Chen et al., 2012).

Overall, the existence of CSCs within the tumour is now accepted as an important feature of cancer and thus, new approaches for studying CSCs are being developed to find novel therapeutic targets.
pyruvate dehydrogenase kinase 1 (PDK1), a negative regulator of pyruvate dehydrogenase (PDH) (Semenza et al., 1994; Kim et al., 2006; Papandreou et al., 2006).

In addition to glucose metabolic changes, increased glutamine metabolism is a common feature of cancer cells (Medina et al., 1992; Souba, 1993). Glutamine is essential in proliferating tumour cells, providing defence mechanisms against oxidative stress, synthesising macromolecules when glucose metabolism is not sufficient and, ultimately, fuelling cellular bioenergetics (Deberardinis et al., 2008). Furthermore, oncogenes such as MYC can influence glutamine metabolism, as they do for glucose metabolism (Wise et al., 2008). MYC stimulates the expression of surface transporters to drive glutamine metabolism and can also regulate glutaminase (GLS) by suppressing the microRNAs responsible for preventing GLS translation (Gao et al., 2009). Glutamine dependency can also modulate the signal transduction pathways that contribute to tumour growth. For example in HeLa cells, glutamine excess leads to a bidirectional transport of this amino acid through membrane transporters, accompanied by an import of other essential amino acids (Nicklin et al., 2009). This mechanism subsequently activates mTORC1, stimulating cell growth and suppressing catabolism and autophagy. ERK (also known as EPHB2) signalling is another example of glutamine-dependent activation found in intestinal epithelial cells (Rhoads et al., 1997; Larson et al., 2007), and in melanoma (Pollock et al., 2003; Ohtani et al., 2008) and glioma cells (Arcella et al., 2005).

A major outcome of both glucose and glutamine metabolism is the production of citrate to support cellular bioenergetics and to produce biomass, namely nucleic acids, proteins and lipids, necessary for cell proliferation. The metabolic fate of citrate produced by these two main metabolic processes is defined by its subcellular localization: mitochondrial citrate is shuttled to the tricarboxylic acid (TCA) cycle, whereas cytoplasmic citrate feeds fatty acid synthesis (Currie et al., 2013).

Lipid metabolism is another major source of metabolic intermediates and energy for processes involved in cell transformation and tumour progression (Santos and Schulze, 2012). Cancer cells can fulfill their strong avidity for lipids either by increasing exogenous lipid uptake or endogenous production through de novo synthesis (Medes et al., 1953; Ookhtens et al., 1984). Lipid synthesis requires several steps to convert citrate into bioactive fatty acids, which are undertaken by ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN) and acyl-CoA synthetase (ACS). Additionally, fatty acid biosynthesis is mainly controlled by sterol regulatory element-binding proteins (SREBPs), a family of transcription factors that bind to sterol regulatory elements and some E-box sequences in the promoters of target genes (Rührig and Schulze, 2016). SREBP1 (also known as SREBF1) can be activated through an AKT-mTORC1 signalling axis, thus promoting lipid synthesis and cell growth (Porstmann et al., 2008). In glioblastomas, the presence of a constitutively active mutant epithelial growth factor receptor (EGFR), the EGFR variant III (EGFRvIII), functions as an enhancer of activated SREBP1 in the nucleus, being correlated with increased levels of FASN and ACC (Guo et al., 2009). In glioblastomas that do not carry EGFR mutations, but instead have AKT pathway activation, silencing of SREBP1 or SREBP2 prevented xenograft growth, confirming the importance of fatty acid metabolism in tumour maintenance (Griffiths et al., 2013; Williams et al., 2013).

Furthermore, stearoyl-CoA desaturase (SCD), an enzyme involved in fatty acid biosynthesis and a target gene of SREBP1, is overexpressed in several human cancers (Li et al., 1994; Falvella et al., 2002; Fritz et al., 2010). Silencing of SCD inhibits lipid synthesis and activates AMP-activated protein kinase (AMPK; also known as PRKAA2), which in turn increases β-oxidation of fatty acids (Dobrzn et al., 2004), leading to tumour size reduction in xenograft models of liver (Budhu et al., 2013), lung (Scaglia and Igal, 2008) and stomach (Roongta et al., 2011) cancers, as well as to inhibition of prostate cancer progression in mice (Fritz et al., 2010).

As a disease that requires building blocks for cell proliferation and survival, cancer is characterized by metabolic remodelling meant for accumulating metabolic intermediates, which are then used as a source of biomass. In the setting of SCs and CSCs, such altered metabolism is also able to shape and regulate the fate and function of these specific cells.

**Metabolic phenotypes of SCs and CSCs**

In general, normal tissue hierarchy holds a metabolic phenotype where multipotent SCs primarily perform glycolysis, while differentiated cells are more reliant on OXPHOS. The first studies on the metabolic phenotype of SCs, again using haematopoietic cells, revealed that SCs reside in hypoxic niches and use mainly glycolysis (Parmar et al., 2007; Suda et al., 2011). Additionally, they have fewer and less mature mitochondria than differentiated cells, resulting in a lower production of reactive oxygen species (ROS) (Jang and Sharkis, 2007; Prigione et al., 2010). In contrast, the differentiated progeny of haematopoietic SCs shift to OXPHOS and increased production of ROS. Although OXPHOS is crucial for the energy demands of complex tissues, SCs might avoid this metabolic phenotype because of the resulting high levels of ROS, which in turn could lead to SC dysfunction (Simsek et al., 2010; Suda et al., 2011; Maryanovich et al., 2015). Therefore, the quiescent state of adult SCs can serve as a protective mechanism against oxidative stress-related damage, ensuring the infinite self-renewal capacity of these cells (Folmes et al., 2012). Furthermore, cellular metabolism can actually control stemness. When reprogramming somatic cells into induced pluripotent SCs (Box 1), the upregulation of glycolytic genes preceded the expression of pluripotency markers, revealing that the metabolic switch from OXPHOS to glycolysis is an early event during SC reprogramming (Folmes et al., 2011; Panopoulos et al., 2012). However, this metabolic pattern can differ between adult SC populations. For example, in intestinal crypts (Box 1), Lgr5+ SCs have increased OXPHOS, whereas Paneth cells (Box 1) preferentially use glycolysis. Paneth cells regulate the renewal of Lgr5+ SCs by producing lactate for the oxidative metabolism of the SCs (Rodriguez-Colman et al., 2017). Apparently, high ROS levels are not harmful to intestinal SCs, but rather induce their differentiation (Yilmaz et al., 2012; Rodriguez-Colman et al., 2017). Another example is satellite muscle cells (Box 1), which are localized in aerobic niches and use mainly OXPHOS; in contrast, committed progenies of these SCs undergo epigenetic reprogramming consistent with a shift to glycolytic metabolism (Ryall et al., 2015).

The metabolic phenotype of CSCs has been studied over the past few years and, contrarily to what was hypothesized, CSCs do not recapitulate the metabolic pattern of adult SCs. In fact, CSCs can primarily rely either on glycolysis or on OXPHOS, mainly depending on the tumour type and TME stimuli that trigger cell plasticity and metabolic reprogramming (Sancho et al., 2016).

**Glycolysis**

Glycolysis is an oxygen-independent metabolic pathway that occurs in the cytosol, generating ATP from the conversion of glucose...
into pyruvate. It consists of three main reactions: phosphorylation of glucose by hexokinase to form glucose 6-phosphate and subsequently fructose 1,6-biphosphate (F1,6P); cleavage of F1,6P into two three-carbon products (glyceraldehyde 3-phosphate and dihydroxyacetone phosphate); and oxidation of these three-carbon products to pyruvate, with ATP production.

As discussed below, CSCs usually have significantly increased glucose uptake and lactate production, together with a decrease in mitochondrial respiration, when compared with their mature non-CSC counterparts (Fig. 1A,B).

In breast cancer cell lines, a switch from mitochondrial respiration to glycolysis decreases the levels of ROS, a mechanism that is essential for the maintenance of stemness in CD44+CD24−/low EPCAM− cells (Dong et al., 2013). Besides, key glycolysis enzymes, such as pyruvate kinase M2 (PKM2; also known as PKM), LDH and glucose-6-phosphate dehydrogenase (G6PDH) have increased activity in breast CSCs, while treatment with 2-deoxyglucose (2DG), a glucose analogue that inhibits hexokinase 2 (HK2), preferentially decreases the proliferation of these cells compared with mature cancer cells, showing that glycolysis is essential for breast CSCs (Ciavardelli et al., 2014). CSCs isolated from human glioblastoma xenografts also have increased glycolysis and low mitochondrial respiration, with a downregulation of the succinate dehydrogenase subunit B (SDHB) and subsequent mitochondrial dysfunction, leading to increased electron leakage and ROS production. Through an ROS-mediated mechanism, the basal levels of HIF-1α and HIF-2α increase, promoting glycolysis by upregulating GLUT1 and HK2 in these human glioblastoma SCs. Furthermore, hypoxia renders glioblastoma SCs resistant to conventional anticancer agents and sensitive to glycolytic inhibition, suggesting that they have a preference for hypoxic environments and a glycolytic metabolism to maintain their stemness (Zhou et al., 2011). Genes involved in glycolysis, namely PFKFB4 caused a reduction in lactate and ATP production, inducing apoptosis of glioblastoma SCs. On the other hand, overexpression of this enzyme was associated with shorter survival of glioblastoma patients (Goidts et al., 2012). In nutrient-deprived conditions, glioblastoma SCs also showed an upregulation of GLUT3 (also known as SLC2A3), a transporter with higher affinity for glucose than GLUT1, in order to preserve glycolysis and maintain stemness (Flavahan et al., 2013). Mao et al. found that two distinct tumour-derived glioblastoma SC subtypes – proneural and mesenchymal glioblastoma SCs – were prominently correlated with the clinically recognized proneural and mesenchymal subtypes of glioblastoma and had distinct dysregulated signalling pathways (Mao et al., 2013). Mesenchymal glioblastoma SCs highly expressed the aldehyde dehydrogenase (ALDH) family, especially the enzyme ALDH1A3, which is involved in glycolysis, among other functions. Inhibition of ALDH1A3 attenuates the growth of this subtype of CSCs, but not of the proneural subtype, suggesting that different CSC populations can have distinct stemness-regulating metabolic pathways (Mao et al., 2013). To further highlight their metabolic variability, glioblastoma SCs were also reported to consume less glucose and produce less lactate, while having higher ATP levels, when compared with differentiated cancer cells (Vlashi et al., 2011). In this study, inhibition of either glycolysis or mitochondrial respiration in CSCs had minimal effect on energy production and only the combined inhibition of both pathways was able to deplete intracellular ATP levels. These CSCs revealed metabolic plasticity features, indicating that targeting specific metabolic pathways individually might not be sufficient to eradicate glioblastoma SCs (Vlashi et al., 2011).

In a mouse model of hepatocellular carcinoma, CSCs expressing Nanog (Box 1) have increased glycolytic activity and fatty acid oxidation (FAO), decreased mitochondrial respiration – owing to cytochrome C oxidase subunit 6A2 (Cox6a2) repression, and inhibition of ROS generation (Fig. 1A), suggesting that a defined metabolic pattern regulates stemness in this model (Chen et al., 2016).

Emmink et al. compared the secretome (Box 1) of CSCs and differentiated cells from colorectal tumours, and observed that CSCs have enriched levels of proteins involved in glycolysis and antioxidant pathways. Furthermore, CSCs secreted high levels of ALDH, which is implicated in the detoxification from anticancer drugs, such as maphosphamide (Box 1). By secreting this drug-detoxifying enzyme, CSCs could not only promote self-preservation, but also protect the differentiated mature cancer cells in their vicinity. Briefly, colorectal CSCs had a survival and antioxidant signature, both of which contributed to therapy resistance (Emmink et al., 2013).

In a metabolic study that used 13C-glucose (Box 1) in ovarian cancer, CSCs showed an enrichment in glycolysis, the PPP and de novo fatty acid synthesis, while having a decrease in mitochondrial respiration and anaerobic flux (Box 1, Fig. 1A); in contrast, mature cancer cells showed increased mitochondrial respiration and higher anaerobic flux (Fig. 1B). Additionally, cisplatin treatment (Box 1) resulted in higher survival of ovarian CSCs in comparison with mature cancer cells. Thus, the authors concluded that this metabolic phenotype of CSCs might contribute to more aggressive tumours and confer increased therapy resistance (Liao et al., 2014).

Mitochondrial respiration
Mitochondrial respiration comprises a series of chemical reactions that occur in the mitochondria, for generating ATP in the presence of oxygen. This metabolic pathway is far more efficient in energy production than glycolysis, generating 36 molecules of ATP per molecule of glucose, as opposed to two molecules of ATP produced in glycolysis.

As briefly mentioned in the previous section, there are reports claiming that CSCs consume less glucose, produce less lactate and are mainlyOXPHOSdependent and less glycolytic than their differentiated counterparts. Leukaemia SCs, although showing low levels of ROS, have an overactive BCL-2-dependent OXPHOS; indeed, inhibiting BCL-2 reduces OXPHOS and can therefore eradicate CSCs (Lagadinou et al., 2013). Likewise, breast cancer cell lines with higher mitochondrial mass and activity were enriched in CSC markers, had a higher efficiency in forming mammospheres (Box 1), had increased tumour initiation capacity in murine xenografts and were resistant to paclitaxel treatment. The authors thus considered mitochondrial mass a potential metabolic biomarker of CSCs (Farnie et al., 2015; Lamb et al., 2015). In ovarian cancer, CSCs also had an OXPHOS-dominated metabolic profile with high ROS production and increased mitochondrial membrane potential (Pastó et al., 2014). Pancreatic ductal adenocarcinoma (PDAC) is another example of OXPHOS-dependent metabolism in CD133 (also known as PROM1)-expressing CSCs, when comparing with mature cancer cells. In this model of patient-derived xenografts, the transcription factor peroxisome proliferator-activated receptor-gamma coactivator (PGC-1α), a regulator of mitochondrial biogenesis, was essential for the OXPHOS phenotype of CSCs, and also for their self-renewal and in vivo tumorigenic capacities. In contrast, differentiated PDAC cells have a MYC-driven glycolytic phenotype, in which MYC overexpression negatively
Fig. 1. General metabolic features of cancer stem cells and mature cancer cells (non-CSCs). (A) Cancer stem cells tend to rely more on glycolysis for ATP synthesis, with overexpression of the glucose transporters GLUT1 and GLUT3, and increased expression of hexokinase 2 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB), pyruvate kinase isoenzyme M2 (PKM2) and lactate dehydrogenase (LDH). Nucleotide biosynthesis is often increased in cancer stem cells owing to overexpression of glucose-6-phosphate dehydrogenase (G6PD) and amino acid synthesis. Glutamine uptake and metabolism to oxaloacetate, together with fatty acid oxidation, also appear to be important mechanisms in cancer stem cells. (B) In contrast, mature cancer cells tend to rely more on OXPHOS for adenosine triphosphate (ATP) production, leading to increased levels of reactive oxygen species (ROS); these cells show low levels of glycolysis and nucleotide synthesis, although this can vary. ASCT2, alanine, serine, cysteine-preferring transporter 2; CPT1, carnitine-dependent transporter 1; FAO, fatty acid oxidation; Glut, glucose transporter (GLUT1 or GLUT3); GOT, glutamate-oxaloacetate transaminase; PPP, pentose phosphate pathway; TCA, tricarboxylic acid.
controls PGC-1α expression and inhibits stemness (Sancho et al., 2015).

Glycolysis and OXPHOS are not necessarily mutually exclusive. Indeed, in a study using breast CSCs, Vlashi et al. reported higher glucose consumption, concomitant with lower lactate and higher ATP production, and with a consistent increase in mitochondrial capacity and activity, compared with the differentiated progeny (Vlashi et al., 2014).

**Glutamine metabolism**

Glutamine metabolism is an anabolic process that produces macromolecules with lower energetic potential (Zheng, 2012). Glutamine can enter cells through the alanine, serine, cysteine-prefering transporter 2 (ASCT2; also known as SLC1A5) and then glutamate, on one hand, can be combined with cysteine and glycine to form reduced glutathione (GSH), which is a major antioxidant that regulates oxidative stress (Estrela et al., 2006); on the other hand, glutamate can be converted into α-ketoglutarate (αKG) to provide TCA cycle intermediates and, ultimately, energy production. This process is relevant for cells that lack citrate production owing to inefficient usage of glucose, constituting an alternative pathway for a truncated TCA cycle (DeBerardinis and Cheng, 2010).

In human haematopoietic SCs, the differentiation to the erythroid lineage completely depends on glutamine metabolism. Even in the presence of erythropoietin, glutamine-depleted haematopoietic SCs were diverted towards a myelomonocytic differentiation. Knockdown of ASCT2 decreased glutamine uptake and inhibited erythroid differentiation. Additionally, the authors demonstrated that the commitment to an erythroid state was not restored by solely feeding the TCA cycle with cell-permeable αKG, but rather it depended on nucleotides produced by glutamine metabolism (Oburogu et al., 2014).

In colorectal cancer cell lines, glutamine metabolism was found to regulate the sensitivity of CSCs to metformin (Box 1) through the AMPK-mTOR pathway. In the presence of glutamine, CSCs from the SW620 cell line showed resistance to metformin, while in the absence of glutamine, these CSCs showed activation of AMPK, suppression of mTOR and became sensitive to metformin treatment. In contrast, CSCs from the HT29 cell line were sensitive to metformin, because they have an activated AMPK pathway. Nevertheless, inhibition of glutamine metabolism in these cells increased the CSC-suppressive effect of metformin. CSCs from both cell lines showed higher expression of ASCT2 in comparison with mature cancer cells, and knockdown of ASCT2 significantly decreased the proportion of CSCs (CD133+ CD44+) in comparison with control small interfering RNA (Fig. 1A). Thus, glutamine metabolism plays an important role in regulating the different responses of CSCs to metformin (Kim et al., 2018).

Another study using PDAC cells demonstrated that a novel noncanonical glutamine pathway is essential for tumour growth and oxidative stress balance in CSCs (Li et al., 2015). Here, glutamine deprivation significantly decreased the expression of stemness markers and the self-renewal potential, and increased intracellular ROS levels, inducing apoptosis. When using glutamine-free medium supplemented with oxaloacetate, the product of the noncanonical glutamine metabolism, these effects were rescued; in contrast, the product of the canonical glutamine metabolism, αKG, did not rescue these effects on CSCs. Additionally, CSCs showed increased expression of GLS and glutamate-oxaloacetate transaminases (GOT1 and GOT2), the latter converting glutamine-derived aspartate to oxaloacetate (Fig. 1A). Inhibition of this pathway sensitized CSCs to radiation, showing that the combination of a glutamine metabolism inhibitor with radiotherapy might be a suitable therapy for PDAC (Li et al., 2015).

**Fatty acid metabolism**

Besides using glucose as a fuel for anabolic processes, cells can derive their energy from fatty acid metabolism. This is essentially controlled by: (1) fatty acid synthesis (FAS), an anabolic process that converts acetyl-CoA to malonyl-CoA and is required for cell growth and proliferation; and (2) fatty acid oxidation (FAO), a catabolic process that breaks down fatty acids to generate acetyl-CoA for anaerobiosis, as well as NADH for the production of ATP (Carracedo et al., 2013).

Haematopoietic SCs are maintained through an FAO pathway downstream of promyelocytic leukaemia protein (PML) and peroxisome proliferator-activated receptor δ (PPARδ). This PML–PPAR–FAO axis is essential for haematopoietic SCs, as it controls the asymmetric division and the fate of these cells (Ito et al., 2008, 2012). Indeed, the SC population can be exhausted by pharmacological or genetic inhibition of any component of this pathway, suggesting that FAO is crucial for stemness (Ito et al., 2012). Another FAO-associated protein, liver kinase B1 (LKB1; also known as STK11), was also found to be essential for haematopoietic SC maintenance (Gan et al., 2010). LKB1 activates and phosphorylates AMPK in response to a decline in the ATP/adenosine monophosphate (AMP) ratio; in turn, AMPK phosphorylates key regulatory proteins involved in fatty acid metabolism to restore ATP levels (Gan et al., 2010; Gurumurthy et al., 2010). Deletion of Lkb1 in mice causes rapid depletion of the haematopoietic SC pool, while also inducing alterations in lipid metabolism, depletion of cellular ATP and mitochondrial defects in Lkb1-deficient bone marrow cells (Gan et al., 2010; Gurumurthy et al., 2010; Nakada et al., 2010).

Adult murine neuronal stem and progenitor cells also have increased activity of fatty acid synthase (FASN), a key enzyme for de novo lipogenesis, in comparison with differentiated progenies (Knobloch et al., 2013). FASN is required for the proliferation of progenitor cells, while quiescent, nonproliferating SCs tended to shift from FAS towards FAO. Low proliferating SCs selectively express the thyroid hormone-responsive protein Spot14 (also known as Thrp), which reduces lipid synthesis and acts as a molecular brake on Fasn-dependent lipogenesis. Thus, neurogenesis is sustained through a tight regulation of fatty acid metabolism, where Fasn and Spot14 play a major role in the regulation of malonyl-CoA levels for the generation of complex fatty acids, which in turn regulate the more quiescent or committed state of the neuronal cells (Knobloch et al., 2013).

Similarly to haematopoietic SCs, quiescent leukaemia-initiating CSCs were also shown to be regulated by FAO. Recent reports revealed that a subpopulation of leukaemia SCs, expressing the fatty acid transporter CD36, can reside in gonadal adipose tissue niches to induce lipolysis and fuel FAO, leading to chemotherapy resistance (Ye et al., 2016). CD36+ cells are also present in oral squamous cell carcinomas and comprise a population of slow-cycling cells expressing the stem cell marker CD44, while also expressing high levels of lipid metabolism genes and being associated with metastasis (Pascual et al., 2017). CD36+ cells were additionally found in other tumours, namely in melanoma and breast cancer, where they also associate with metastatic potential (Pascual et al., 2017). These studies suggest that a subset of highly aggressive CSCs obtain their energy through FAO, thus revealing a...
specific metabolic profile required during metastasis that might be a potential target for the eradication of CSCs. Furthermore, in hepatocellular carcinoma, Nanog induces a metabolic reprogramming of CSCs: a decrease in mitochondrial respiration and an enhanced reliance on glycolysis and, additionally, an upregulation of FAO genes to support the self-renewal of these cells (Chen et al., 2016) (Fig. 1A). In contrast, de novo lipid synthesis is increased in glioma CSCs compared with mature glioma cells, owing to high Fasn expression. Fasn inhibition reduces stem cell marker expression while increasing differentiation markers and decreasing the proliferation and migration of CSCs (Yasumoto et al., 2016) (Fig. 1A). Other lipid metabolism enzymes, such as arachidonic acid 5-lipoxygenase (Alox5), which is involved in the synthesis of leukotrienes (Box 1) from arachidonic acid, and acyl-CoA synthetase very-long-chain 3 (ACSVL3; also known as SLC27A3), a key enzyme in fatty acid activation for the formation of fatty acyl-CoA, were also shown to support glioblastoma CSCs self-renewal and to induce tumour xenograft formation (Wang et al., 2011; Sun et al., 2014). Finally, colorectal CSCs have high levels of lipid droplets, which correlate with the expression of stem cell markers. CSCs with more lipid droplets showed a higher tumorigenic capacity upon xenotransplantation, suggesting that lipid metabolism can mediate stemness in colorectal cancer (Tirinato et al., 2015).

Other metabolic features
Mutations in genes that encode metabolic enzymes have revealed yet another mechanism of cancer stemness regulation by metabolic reprogramming. In leukaemia, mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2, respectively) were specifically associated with CSC regulation. These mutations alter the normal IDH1/2-mediated conversion of isocitrate to αKG into an aberrant conversion of αKG to the analogue, 2-hydroxylglutrate (2-HG). This metabolite accumulates intracellularly and inhibits tet methyllysosine dioxygenase 2 (TET2) function by competing with its cofactor αKG. In the presence of mutant IDH1/2 or TET2 depletion, the self-renewal potential of haematopoietic CSCs increases and differentiation is impaired, which suggests a pro-leukaemic phenotype (Figueroa et al., 2010; Cimmino et al., 2011; Kats et al., 2014).

Purine synthesis is another metabolic mechanism that controls stemness in brain CSCs. Wang et al. observed that CSCs show upregulation of enzymes involved in purine synthesis for the production of purine nucleotides that serve as building blocks for DNA and RNA (Wang et al., 2017b). These include the enzymes phosphoribosylpyrophosphate synthetase 1 (PRPS1) and phosphoribosyl pyrophosphate amidotransferase (PPT1) to synthesize inosine monophosphate (IMP), adenylosuccinicate lyase (ADSL) and adenylosuccinate synthase (ADSS) to synthesize AMP, and guanine monophosphate synthase (GMPS) and IMP dehydrogenase 1 (IMPDH1) to synthesize guanosine monophosphate (GMP). Genetic perturbations of these enzymes caused a decrease in CSC growth and maintenance and abrogated tumour formation in immunodeficient and immunocompetent mouse models, by depleting the intracellular pools of purine nucleotides. In contrast, targeting purine biosynthesis did not affect differentiated glioblastoma cells, which collectively supports the selective dependence of brain CSCs on the purine synthesis pathway (Wang et al., 2017b).

Lysine catabolism was also found to be essential to promote the self-renewal of colorectal CSCs and induce liver metastasis. Colorectal CSCs expressing the thrombopoietin-binding receptor CD110 (also known as MPL) signal through thrombopoietin by activating lysine degradation. This generates acetyl-CoA, which is used for the acetylation of the LDL receptor-related protein 6 (LRP6). This acetylation in turn recruits casein kinases that phosphorylate LRP6 for the activation of WNT protein signalling and regulation of CD110+ CSC self-renewal. Furthermore, lysine catabolism in these cells promoted the generation of glutamate, which enhances cysteine uptake and GSH synthesis. Thus, CD110+ CSCs are able to modulate their redox status by lysine catabolism, promoting self-renewal, drug-resistance and liver metastasis (Wu et al., 2015).

Normal SCs seem to have a more consistent metabolic phenotype and control of their molecular pathways (Ito and Suda, 2014). As discussed in this section, CSCs, although lacking a common metabolic pattern across cancer types, clearly have a distinctive metabolic phenotype compared with their mature cancer cell counterparts. The number of publications addressing the metabolism of CSCs is still small, and discrepancies, such as different environmental stimuli in the experimental setting, might explain the contradictory results. As an example, many of the studies discussed in this Review favour glycolysis by growing cells in high glucose and high oxygen culture conditions that fail to recapitulate tissue homeostasis and TME conditions in vivo. Indeed, the TME is an important factor for cellular metabolism, as it creates a symbiotic system where, for example, highly glycolytic stromal cells generate metabolic products that can be used by cancer cells; these, in turn, shift their metabolism towards OXPHOS and can potentially trigger a reprogramming to more stem-like states (Pavlides et al., 2009; Migneo et al., 2010; Martinez-Outschoorn et al., 2011; Nakajima and Van Houten, 2013; Davidson et al., 2016). Such organization cannot be reproduced when using established cancer cell lines in in vitro systems that lack a suitable TME, resulting in inconsistent findings and major differences concerning the metabolic phenotypes in in vitro and in vivo settings. Importantly, the very definition of CSCs and the experimental designs for their isolation and characterization vary across studies, which also contributes to the inconsistency of results.

Although these findings still lack robustness and further validations, the specific metabolic features of CSCs have been tested as potential therapeutic targets and should be taken into account for future cancer therapies.

Metabolism as a therapeutic target for CSCs
Cancer cell plasticity and the acquisition of a quiescent state are thought to be important drivers of drug resistance. Actually, several findings support the fact that residual dormant clones, which resist the antiproliferative chemotherapeutic treatment, can become dominant and cause tumour relapse (Chen et al., 2012; Kreso et al., 2013; Kurtova et al., 2015; Liau et al., 2017). Along with the emergent reports aiming at characterizing the molecular mechanisms that govern stemness in cancer, several therapeutic approaches have been developed and tested for the elimination of CSCs. However, no anti-CSC therapy has shown sufficient effectiveness in order to be approved for clinical use. Thus, therapies targeting the metabolic networks that mediate cancer cell stemness could be an innovative and efficient strategy to target this cell population.

Several studies using mouse models of cancer have shown that targeting oxidative metabolism, the main source of energy for CSCs in these models, sensitizes this population to chemotherapies, thus leading to their depletion. One example is the population of slow-cycling JARID1B+ cells in melanoma that has an upregulation of OXPHOS enzymes. Treatment of melanoma cells with several drugs, including cisplatin and vemurafenib, an inhibitor of mutant
BRAF, causes an enrichment of the JARID1B+ population and subsequent therapy resistance. When inhibiting OXPHOS using either ATP-synthase inhibitors (oligomycin and Bz-423) or complex I inhibitors (rotenone and phenformin), JARID1B+ cells were sensitized to the anticancer agents that initially failed to eliminate them (Fig. 2). Even among functionally and genetically heterogeneous melanomas, this combined approach of treatment was effective, because cytotoxic agents mostly eliminate the rapidly dividing cells, while the metabolic inhibitors could target and sensitize slow-cycling cells (Roesch et al., 2013). Another example is PDAC, where tumourigenesis is essentially driven by mutant KRAS. Targeting this oncogene only leads to tumour shrinkage, while sparing a fraction of cells with CSC features that have prominent expression of genes governing mitochondrial function and strong reliance on OXPHOS for cellular energetics. These CSCs showed high sensitivity to OXPHOS inhibitors (preferentially to oligomycin) that, when combined with targeted therapy for the KRAS pathway, could eliminate the tumour and prevent recurrence (Viale et al., 2014). In other studies, however, the mitochondrial inhibitor metformin was not enough to eliminate some CSC clones, possibly due to the heterogeneity and plasticity of PDAC cells and their intermediate glycolytic/respiratory phenotype. These CSC clones showed an upregulation of MYC, which regulates PGC-1α levels and, subsequently, controls the metabolic phenotype of resistant CSC clones. Genetic or pharmacological targeting of MYC reversed this phenotype by increasing the CSC dependency on OXPHOS and sensitizing them to metformin (Sancho et al., 2015) (Fig. 2). Furthermore, the commonly used inhibitor of thymidine synthesis, 5-fluorouracil (5-FU), was shown to selectively target CSCs in colon cancer. These cells undergo a metabolic reprogramming favouring OXPHOS and decreasing the PPP, a mechanism found to be responsible for 5-FU resistance. Thus, combined treatment with 5-FU and metformin abolished drug resistance and effectively diminished the population of CSCs (Denise et al., 2015). In agreement with these findings, treatment of CSCs from epithelial ovarian cancer with different inhibitors of the electron transport chain, namely oligomycin, antimycin and rotenone, could lead to apoptosis of CSCs (Pastó et al., 2014) (Fig. 2).

Targeting glycolytic enzymes also presented promising results in the mesenchymal subtype of glioblastoma CSCs that overexpress ALDH1A3. Radiation treatment of proneural and mesenchymal subtypes of these cells has shown that mesenchymal CSCs are resistant and highly aggressive compared with proneural CSCs. Furthermore, irradiation of proneural CSCs results in an upregulation of mesenchymal-associated markers, and this effect could be attenuated only when inhibiting ALDH1A3. Therefore, the subset of glioblastoma patients with a mesenchymal signature might benefit from ALDH inhibition for the eradication of highly aggressive CSCs (Mao et al., 2013). In another study, the combination of conventional anticancer agents, such as doxorubicin, with a derivative of 3-bromopyruvate that inhibits glycolysis, effectively killed glioblastoma CSCs in vitro and inhibited tumour formation in vivo (Zhou et al., 2011) (Fig. 2).

Furthermore, the metabolic shift from glycolysis to mitochondrial respiration, caused by dichloroacetate treatment, increased ROS and induced apoptosis in glioblastoma CSCs, both in vitro and in vivo (Michelakis et al., 2010) (Fig. 2).

Lipid metabolism has been also tested as a promising target for the eradication of drug-resistant CSCs. Etomoxir, an inhibitor of the carnitine-dependent transporter CPT1 (also known as CPT1A) and FAO, was able to eradicate ~50% of quiescent leukaemia SCs in primary human myeloid leukaemia samples, and sensitize
leukaemia cells to apoptosis-inducing agents in a murine model (Samudio et al., 2010) (Fig. 2). In hepatocellular carcinoma, the restoration of OXPHOS by Cox6a2 or Cox15 overexpression and/or inhibition of FAO by etomoxir sensitized CSCs to sorafenib treatment, suggesting that reprogramming CSC metabolism by either OXPHOS restoration or FAO inhibition can be an effective therapy in these tumours (Chen et al., 2016) (Fig. 2). Furthermore, slow cycling cells with CSC features and a high capacity to initiate metastasis could be neutralized by antibodies targeting CD36, almost completely inhibiting metastasis in mouse models of oral cancer. These CSCs exhibit high levels of the fatty acid receptor CD36 and lipid metabolism genes, thus providing a novel therapeutic target for the elimination of the metastatic potential of these cells (Pascual et al., 2017).

Another approach for targeting CSC via mitochondrial mass and metabolism is the use of antibiotics, an approach based on the symbiotic theory claiming that mitochondria originated from aerobic bacteria. Several approved antibiotics, such as tetracyclines, salinomycin or erythromycins have been shown to reduce stem properties in cancer, induce differentiation and inhibit tumour growth in vivo (Gupta et al., 2009; Zhou et al., 2013).

Collectively, direct targeting of metabolic enzymes or indirect targeting by inhibiting the upstream mediators of metabolic pathways, can lead to CSC eradication in distinct tumour types, mostly in combination with standard anticancer agents (Fig. 2). However, cancer cell plasticity represents a major technical challenge in the design of efficient therapies targeting CSCs. Finally, the notion that by eliminating CSCs, one can achieve cancer cure, requires more reliable and consistent experiments with CSCs in their intact environment, which is still an open field that needs to be addressed.

Conclusions

The notion that metabolism plays a major role in the maintenance of CSCs is an emerging concept that might provide novel, metabolism-related targets for innovative therapeutic approaches. Although the CSC field has grown exponentially in the last decades, substantial questions remain to be addressed. Specifically, there is an urge to define the mechanisms behind the TME control over the metabolic plasticity of CSCs, and to demonstrate whether CSCs themselves are metabolically heterogeneous and modulate tumourigenesis according to specific stimuli. It is crucial that future studies ameliorate the experimental settings used so far, in order to account for the TME and preserve the in vivo structure of tumours.

This article is part of a special subject collection 'Cancer Metabolism: models, mechanisms and targets', which was launched in a dedicated issue guest edited by Almut Schulze and Maria Yuneva. See related articles in this collection at http://dmm.biologists.org/collection/cancermetabolism.

Competing interests

The authors declare no competing or financial interests.

Funding

Funding was provided by NOSTER2020 (NORTE-01-0145-FEDER-000020). J.P. is financed through a grant from Fundação para a Ciência e a Tecnologia (SFRH/BD/105684/2015). I3S-Ipatimup is an Associated Laboratory of the Portuguese Ministry of Science, Technology and Higher Education that is partially supported by Fundação para a Ciência e a Tecnologia.

References

At-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. and Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988.

Arcella, A., Caprinelli, G., Battaglia, G., D’onofrio, M., Santoro, F., Ngombu, R. T., Bruno, V., Casolinu, P., Giangaspero, F. and Nicotelli, F. (2005). Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol. 7, 236-245.

Auffinger, B., Tobias, A. L., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D. and Rich, J. N. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.

Battle, E. and Clevers, H. (2017). Cancer stem cells revisited. Nat. Med. 23, 1124-1134.

Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E. and Vousten, K. H. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120.

Blanpain, C. and Simons, B. D. (2013). Unravelling stem cell dynamics by lineage tracing. Nat. Rev. Mol. Cell Biol. 14, 489-502.

Bolshakov, I. D., Razorenova, O. V., Van De Rijn, M., Swetter, S. M., Johnson, D. L., Ly, D. P., Butler, P. D., Yang, G. P., Joshua, B., Kaplan, M. J. et al. (2010). Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466, 133-137.

Bonnet, D. and Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.

Boumahdi, S., Driessens, G., Lapouge, G., Rorive, S., Nassar, D., Le Mercier, M., Delatte, B., Cauwe, A., Lenglese, S., Nkusi, E. et al. (2014). SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511, 246-250.

Boveri, T. (1892). Ueber die Entstehung des Gegensatzes zwischen den Geschlechtszellen und den somatischen Zellen bei Ascaris megalopoechea, nebst Bemerkungen zur Entwicklungsgeschichte der Nematoden. Sitzungsber. Ges. Morphol. Physiol. München 8, 112-225.

Budhu, A., Roessler, S., Zhao, X., Yu, Z., Forgues, M., Ji, J., Karoly, E., Qin, L. X., Ye, Q. H., Jia, H. L. et al. (2013). Integrated metabolome and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 144, 1066-1075.e1061.

Carracedo, A., Cantley, L. C. and Pandolfi, P. P. (2013). Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227-232.

Chen, R., Nishimura, M. C., Bumbaca, S. M., Kharbanda, S., Forrest, W. F., Kasmam, I. M., Greve, J. M., Soriano, R. H., Gilmour, L. L., Rivers, C. S. et al. (2010). A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17, 362-375.

Chen, L. X., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G. and Parada, L. F. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526.

Chen, C.-L., Uthaya Kumar, D. B., Punj, V., Xu, J., Sher, L., Tahara, S. M., Hess, S. and Machida, K. (2016). NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metab. 23, 206-219.

Ciavardelli, D., Rossi, C., Barcaroli, D., Volpe, S., Consalvo, A., Zucchelli, M., De Cola, A., Scavo, E., Carollo, R., Dahan, P., Martinez Gala, J., Delmas, C., Monferran, S., Malric, L., Zentkowski, D., Lubrano, V., Toulas, C., Cohen-Jonathan Moyal, E. and Lemarie, A. (2011). TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 9, 193-204.

Civenni, G., Walter, A., Kobert, N., Mihic-Probst, D., Zipser, M., Belloni, B., Seifert, B., Lopez, H., Dummer, R., van den Broek, M. et al. (2011). Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 71, 3098-3109.

Clevers, H. (2011). The cancer stem cell: premises, promises and challenges. Nat. Rev. Cancer 11, 313-315.

Cortina, C., Turon, G., Stork, D., Hernando-Momblama, X., Sevillano, M., Aguilleria, M., Tosi, S., Merlos-Suarez, A., Stephan-Otto Attolini, C., Sancho, E. et al. (2017). A genome editing approach to study cancer stem cells in human tumours. EMBO Mol. Med. 9, 869-879.

Cristofanilli, M., Schulze, A., Zechnier, R., Walther, T. C. and Farese, R. V. Jr. (2013). Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153-161.

Dahan, P., Martinez Gala, J., Deimas, C., Monferran, S., Malric, L., Zentkowski, D., Lubrano, V., Toulas, C., Cohen-Jonathan Moyal, E. and Lemarie, A. (2014). Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis. 5, e1543.

Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., Bauer, M. R., Jha, A. K., O’Brien, J. P., Pierce, K. A. et al. (2016). Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23, 517-528.

Deberardinis, R. J. and Cheng, T. (2010). Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324.
Deberardinis, R. J., Sayed, N., Ditsworth, D. and Thompson, C. B. (2008). Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54-61.

Denise, C., Paoli, P., Calvani, M., Taddei, M. L., Giannoni, E., Kopetz, S., Kazmi, S. M. A., Pia, M. M., Pettazzoni, P., Sacco, E. et al. (2015). 5-fluorouracil-resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncogene 34, 4170-4172.

Depraz, J., Vertommen, D., Alessi, D. R., Hue, L. and Rider, M. H. (1997). Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J. Biol. Chem. 272, 17269-17275.

Dobrzyń, P., Dobrzyń, A., Miyazaki, M., Cohen, P., Asinam, E., Hardie, D. G., Friedman, J. M. and Ntambi, J. M. (2004). Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. USA 101, 6049-6044.

Dong, M., Yoshioka, T., Yang, Y., Fan, T. W. M., Miyriala, S., Lin, Y., Yao, J., Shi, J., Kang, T. et al. (2013). Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23, 316-321.

Driessens, G., Beck, B., Auwae, A., Simons, B. D. and Blanpain, C. (2012). Defining the mode of tumour growth by clonal analysis. Nature 488, 527-530.

Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafello, E., Ma, Q., Gorski, R., Cleaver, S. et al. (2010). Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 1711-1723.

Elistrom, R. L., Bauer, D. E., Buzzi, M., Karna, L., Harris, M. H., Plas, D. R., Zhuang, H., Cialli, R. M., Alavi, A., Rudin, C. M. et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892-3899.

Emmink, B. L., Verheem, A., Van Houdt, W. J., Steller, E. J., Goavert, K. M., Pham, T. V., Piersma, S. R., Borel Rinkes, I. H. M., Jimenez, C. R. and Krakiwsky, D. P. (2009). The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J. Proteomics 91, 84-96.

Erao, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C. and De Maria, R. (2010). Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Cell Death Differ. 17, 110-121.

Eramo, A., Lotti, F., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C. and De Maria, R. (2009). c-Myc suppression and therapy. Mol. Cancer Ther. 8, 3056-3067.

Ermakova, M. M., Dragani, T. A. and Feo, F. (2013). The secretome of colon cancer stem cells contains drug-resistant factors. Oncotarget 4, 658-675.

Erbil, K., Yucsel, K., Zecherle, A., Dikicioglu, A., Yilmaz, B., Tekes, A., Ozcan, O., Avigan, D. E., Schafer, Z. T., Evans, R. M., Suda, T., Lee, C.-H. et al. (2012). A PML-PARP-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat. Med. 18, 1350-1356.

Jang, Y.-Y. and Sharkis, S. J. (2007). A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110, 3056-3063.

Kats, L. M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Staley, K., Karnick, R., Meissner, A., Small, D. et al. (2014). Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 14, 329-341.

Kim, J.-W., Theryncky, L., Semeznia, G. L. and Dang, C. V. (2006). HIF-1-mediated lipogenesis in basal-like breast cancer. Mol. Cancer Ther. 5, 1233-1238.

Koizumi, M., Braun, S. M., Zirkurcn, L., Von Schoultz, C., Zamboni, N., Arauzo-Bravo, M. J., Kovacs, W. J., Karalay, O., Suter, U., Machado, R. A. C. et al. (2013). Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis. Nature 493, 226-230.

Kozar, S., Morrissey, E., Nicholson, A. M., Van Der Heijden, M., Zeclori, C. H., Kemp, R., Tavare, S., Vermeulen, L. and Winton, D. J. (2013). Continuous clonal labelling reveals small numbers of functional stem cells in intestinal crypts and adenomas. Cell Stem Cell 13, 623-633.

Kreso, A., O'Brien, C., van Galen, P., Gao, O. I., Notta, F., Brown, A. M. K., Ng, K., Ma, J., Wiohlnds, E., Dunant, C. et al. (2013). Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543-548.

Kretzschmar, K. and Watt, F. M. (2012). Lineage tracing. Cell 148, 33-45.

Kurtova, A. V., Xiao, M. O., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L. et al. (2015). Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209-213.

Kazandinou, E. D., Sach, A., Callahan, K., Rossi, R. M, Neuringer, S. J., Minihajjuda, M., Ashton, J. M., Pei, S., Grose, V. O’ dwyer, K. M. et al. (2013). BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329-341.

Lamb, R., Bonuccelli, G., Orsini, A., Mcdonnell, L. A., Florio, M., Smith, D. L., Bevilacqua, G., Mazzanti, C. M., McDonnell, L. A., Naccarato, A. G. et al. (2015). Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: understanding WNT/FGF-driven anabolic signalling. Oncogene 34, 3043-3047.

Landiop, A., Silvasti, N., Moutar, K., Caligni, M. A. and Dick, J. E. (1994). A cell initiating human acute myelid leukemia after transplantation bei SCID mice. Nature 367, 645-648.
Larson, S. D., Li, J., Chung, D. H. and Evers, B. M. (2007). Molecular mechanisms contributing to glutamine-mediated intestinal cell survival. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G1262-G1271.

Li, J., Ding, S.-F., Habib, N. A., Fermor, B. F., Wood, C. B. and Gilmour, R. S. (1994). Purification and characterization of a DNA for human styryl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues. Int. J. Cancer 57, 348-352.

Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F. and Simeone, D. M. (2007). Identification of pancreatic cancer stem cells. Proc. Natl. Acad. Sci. USA 104, 10370-10375.

Li, D., Fu, Z., Chen, R., Zhao, X., Zhou, Y., Zeng, B., Yu, M., Zhou, Q., Lin, Q., Gao, W. et al. (2015). Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy. Oncotarget 6, 31151-31163.

Liao, J., Qian, D., Tchabo, N., Mhawech-Fauceglia, P., Beck, A., Qian, Z., Wang, X., Xu, Y., Wu, W. J., Lele, S. B., Morrison, C. D. et al. (2014). Ovarian cancer spheroid cells with stem-cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant PLOs ONE 9, e84941.

Liau, B. A., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J. et al. (2017). Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20, 233-246.e237.

Manning, B. D. and Cantley, L. C. (2007). AKT/PI3K signalling: navigating downstream. Cell 129, 1261-1274.

Mao, P. H., Li, K., Kim, S.-H., Li, P., Santana-Santos, L., Luthra, S., Michelakis, E. D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, M., Morfouace, M., Lalier, L., Oliver, L., Cheray, M., Pecqueur, C., Cartron, P.-F. and Migneco, G., Whitaker-Menezes, D., Chiavarina, B., Castello-Cros, R., Pavlides, Medema, J. P. and Meacham, C. E. and Morrison, S. J. (2009). Lkb1 regulates cell cycle progression of glioblastoma stem cells. Nature 468, 653-658.

Oburoglu, L., Harada, T., Funasaki, Y., Nakao, K., Takahara, C., Abdel-Daim, M., Sakai, N., Saito, N., Nishigori, C. and Alba, A. (2008). Metabolic glutamate receptor 1 subtype-1 is essential for in vivo growth of melanoma. Oncogene 27, 7162-7170.

Oktiens, M., Kannan, R., Lyon, I. and Baker, N. (1984). Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol. 247, R146-R153.

Ootus, R., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Woldring, D., Lee, L. A. and Dang, C. V. (2000). Deregulation of glucose transporter 1 and glycogenic gene expression by c-Myc. J. Biol. Chem. 275, 21797-21800.

Pollock, P. M., Cohen-Solal, K., Sood, R., Namkoong, J., Martino, J. J., Koganti, P., Pras-Raves, M., Sacchetti, A., Sackstein, R. and Down, J. D. (2007). Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc. Natl. Acad. Sci. USA 104, 5431-5436.

Pascual, G., Avgustinova, A., Mejetta, S., Martin, M., Castellanos, A., Attolini, C. S.-O., Berenguer, A., Prats, N., Tort, A., Hueto, J. A. et al. (2017). Targeting metabolic dependencies of cancer cells through the fatty acid receptor CD36. Nature 541, 41-45.

Pastó, B., Lill, D., Recio, E., Martínez, J. A., Godo, I., Punyet, S., Pasto, P. M., Lameriniere, C., Serrano, M., Ariño, D., Royo, I. et al. (2014). Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget 5, 4305-4319.

Pavlidis, N., Mauch, P., Vergilio, A., Sackstein, R. and Down, J. D. (2007). Adaptation to high oxygen tension by human glioma cells. J. Cell Biol. 178, 381-388.

Prigione, A., Fauler, B., Lurz, R., Lehrach, H. and Adjaye, J. (2007). The CD36 receptor subtype-1 is essential for in vivo growth of melanoma. J. Biol. Chem. 282, 40010-40018.

Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M. and Morrison, S. J. (2007). Identification of pancreatic cancer stem cells with stem cell-like properties contribute to tumor generation, metastasis and chemoresistance. Cancer Res. 67, 348-352.

Ramalho-Santos, M. and Willenbring, H. (2007). Tumour heterogeneity and cancer cell plasticity. Nature 451, 108-112.

Raspetonyi, P. and Medema, J. P. (2017). Intra-tumor heterogeneity from a cancer stem cell perspective. Mol. Cancer 16, 41.

Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., Ramalho-Santos, M. and Willenbring, H. (2007). Identification of pancreatic cancer stem cells capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110.

Rice, E., Mitchell, P. K., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F. and Simeone, D. M. (2007). Identification of pancreatic cancer stem cells. Proc. Natl. Acad. Sci. USA 104, 10370-10375.

Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., Ramalho-Santos, M. and Willenbring, H. (2007). Identification of pancreatic cancer stem cells capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110.

Roest, J. M., Argenzio, R. A., Chen, W., Rippe, R. A., Westwick, J. K., Cox, A. D., Berschneider, H. M. and Brenner, D. A. (1997). L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. Am. J. Physiol. 272, G943-G953.

Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C. and De Maria, R. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115.

Rodríguez-Colman, M. J., Schewe, M., Meerlo, M., Stigter, E., Gerrits, J., Pras-Raves, M., Sacchetti, A., Hornsveld, M., Oost, K. C., Snippert, H. J. et al. (2017). Interplay between metabolic identities in the intestinal crypt supports stem cell function. Science 354, 47-52.

Roediger, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabrowski, S. E., Bradford, P. A., Vultur, A., Basu, D., Gimotty, P., Vogt, T. and Herlyn, M. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594.

Roediger, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E. et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the
Rohrig, F. and Schulze, A. (2016). The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer 16, 732-749.

Ronnoen, U. V., Jiang, Y., Xyseck, R.-P., Fargnoli, J., Henley, B. J., Yang, W.-P., Zhu, J., Madredi, M. T., Lawrence, R. M. et al. (2011). Cancer cell dependence on unsaturated fatty acids implicates stearyl-CoA desaturase as a target for cancer therapy. Mol. Cancer Res. 9, 1551-1561.

Ryall, J. G., Dell’Orso, S., Derouli, A., Juan, A., Zare, H., Feng, X., Clermont, D., Koulimis, M., Gutierrez-Cruz, G., Fuclo, M. et al. (2015). The NAD+ dependent SIRT1 deacetylase translates a metabolic switch into regulatory epigenetics in skeletal muscle stem cells. Cell Stem Cell 16, 171-183.

Samudio, I., Hormancey, R., Flegi, M., Kantarjian, H., Konopleva, M., Korchin, B., Kaluvarachchi, K., Bornmann, W., Duvvuri, S., Tegtmeyer, H. et al. (2010). Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 120, 126-132.

Sancho, P., Burgos-Ramos, E., Tavares, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graño, A. et al. (2015). MYC/PGC-1α-talpa balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 22, 590-605.

Sancho, P., Barneda, D. and Heeschen, C. (2016). Hallmarks of cancer stem cell metabolism. Br. J. Cancer 114, 1305-1312.

Santos, C. R. and Schulze, A. (2012). Lipid metabolism in cancer. FEBS J. 279, 2610-2623.

Scaglia, N. and Igal, R. A. (2008). Inhibition of Stearoyl-CoA Desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis. Int. J. Oncol. 33, 839-850.

Schattong, T., Murphy, G. F., Frank, N. Y., Yamaoka, K., Waaga-Gasser, A. M., Gasser, M., Zhan, Q., Jordan, S., Duan, L., Weishaupt, C. et al. (2008). Identification of cells initiating human melanomas. Nature 451, 349-354.

Scheppach, A. G., Snippet, H. J., Stange, D. E., van den Born, M., van Es, J. H., van de Wetering, M. and Clevers, H. (2012). Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337, 730-735.

Schober, M. and Fuchs, E. (2011). Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. J. Clin. Invest. 121, 2111-2120.

Semenza, G. L., Roth, P. H., Fang, H. M. and Wang, G. L. (1994). Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269, 23757-23763.

Shackleton, M., Quintana, E., Fearon, E. R. and Morrison, S. J. (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829.

Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Wu, Q., Dang, G., Jungmann, R. A., Dalla-Semenza, G. L., Roth, P. H., Fang, H. M. and Wang, G. L. (2011). CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Oncol. 39, 161-169.

Shmelkov, S. V., Butler, J. M., Hooper, A. T., Hormigo, A., Kushner, J., Milde, T., Kaluarachchi, K., Bornmann, W., Duvvuri, S., Taegtmeyer, H. et al. (2011). Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. Nat. Neurosci. 20, 661-673.

Shokat, K. M., Argus, J. P., Zhu, Y., Williams, J. L., Rheinbay, E., Gillespie, S. M., Patel, A. P., Wakimoto, H., Rabkin, S., R., Potze, L., Marotta, R., Ruffilli, R., Rajamanickam, V. P. et al. (2015). Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells 33, 35-44.